COVID-19 Preventive Behavior in African Americans
2021年11月2日 更新者:Johns Hopkins University
Optimizing Tailored-feedback Message to Promote Adherence Behavior to Prevent COVID-19 in African Americans
The Center Disease Control has published a set of guidelines to contain the spread of the virus, since it is known to spread from person-to-person.
Given the vaccine and specific antiviral treatment for Coronavirus disease (COVID-19) remain under development and will take months or years to develop, intermittent and sustained preventive behaviors may be needed into 2022 unless effective treatments or vaccines are developed.
Thus, effectively implementing preventive behaviors remains a critical step in bringing the pandemic under long-term control.
Leveraging the ecological momentary assessment (EMA) method developed in the parent R01 for smartphones, which allows for real-time data collection on individual's behaviors, the investigators propose a prospective single arm and longitudinal study to examine the effectiveness of self-monitoring EMA (SM-EMA) in promoting adherence to COVID-19 preventative behaviors.
SM-EMA users will download the smartphone app which includes: (1) instructional videos to provide knowledge of preventative behaviors; (2) self-monitoring of preventative behaviors during intervention and follow-up phases; (3) tailored-feedback messages to encourage preventative behaviors; and (4) mobile-enabled website to provide an interactive learning platform.
If proven efficacious, this intervention could be efficiently disseminated to reach the larger public and foster preventive behaviors into self-management as effective strategies for long-term control of the COVID-19 pandemic.
調査の概要
詳細な説明
Given the vaccine and specific antiviral treatment for COVID-19 will take months or years to develop and finalize, preventive behaviors remain the most effective strategy thus far and may be needed until 2022 to control the pandemic.
African Americans, who have 3-fold higher infection rate and 6-fold higher death rate compared to the white counterparts, are an especially vulnerable population to COVID-19.
Immediately initiating a project that promotes and maximizes adherence to preventative behaviors is vital to addressing the ongoing COVID-19 pandemic.
The investigators propose a prospective single arm and longitudinal study to examine the effectiveness of SM-EMA in promoting adherence to COVID-19 preventative behaviors.
The intervention will include two daily pop-up messages during Week 1 (one in the morning and one in the afternoon), one daily pop-message in Week 2, and two pop-up messages a week in Weeks 3 and 4. The duration for the intervention will be four weeks.
The study outcomes will be collected at baseline (pre-intervention, T1), post-(completion of the intervention, T2, primary endpoint), and monthly follow-up for three months (T3-T5).
The total study duration will be four months.
研究の種類
介入
入学 (実際)
250
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21205
- Johns Hopkins School of Nursing
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
60年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
はい
受講資格のある性別
全て
説明
Inclusion Criteria:
- African American aged 60 or older
- Able to read and write English
- Willing to commit to use the smartphone app with the pop-up messages and then four follow-up surveys (total four months).
Exclusion Criteria:
- No children or others aged 59 years or younger
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Sm-EMA
Participants will receive the Self-monitoring ecological momentary assessment behavior change tool.
|
Self-monitoring ecological momentary assessment behavior change tool to promote adherence to a desired behavior (i.e.
COVID-19 preventative behaviors).
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change in Knowledge Test score as assessed by a questionnaire
時間枠:Pre-intervention, Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
It is a measure of one's knowledge of COVID-19 preventative behaviors, with a score range of 0-18, higher scores indicating better knowledge.
|
Pre-intervention, Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
Change in Self-efficacy as assessed by self-efficacy questionnaire
時間枠:Pre-intervention, Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
It is a measure of one's belief that they will be successful in reaching a behavior goal, with 6-items of questionnaire, with a score of 0-60, higher score indicating higher level of self-efficacy.
|
Pre-intervention, Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
Change in preventive Behavior Score
時間枠:Pre-intervention, Daily during intervention week 1 and bi-weekly during intervention weeks 3-4, Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
It is a measure of one's adherence to COVID-19 preventative behaviors, with a score range 0-18, higher score indicating worsening preventive behaviors.
|
Pre-intervention, Daily during intervention week 1 and bi-weekly during intervention weeks 3-4, Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
Change in System Usability Scale (SUS) score
時間枠:Immediately Post-intervention
|
It is used to assess the global view of the participant's assessment about usability of SM-EMA, with a score of 1-7, higher score indicting more useable for the app.
|
Immediately Post-intervention
|
Change in Global Impression of Change as assessed by a questionnaire
時間枠:Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
It is a single item used to assess the participant's perceived behavior change, with a score of 1-7, higher score indicating better global impression of change.
|
Immediately Post-intervention, 1, 2, and 3 months Post-intervention
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- 主任研究者:Chao Hsing Yeh, PhD、Johns Hopkins School of Nursing
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2021年2月5日
一次修了 (実際)
2021年10月30日
研究の完了 (実際)
2021年10月30日
試験登録日
最初に提出
2021年1月6日
QC基準を満たした最初の提出物
2021年1月6日
最初の投稿 (実際)
2021年1月7日
学習記録の更新
投稿された最後の更新 (実際)
2021年11月3日
QC基準を満たした最後の更新が送信されました
2021年11月2日
最終確認日
2021年1月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IRB00250644
- 3R01AG056587-03S1 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
COVID19の臨床試験
-
Ricardo Pereira MestreInstitute of Oncology Research (IOR); Istituto Cantonale di Patologia完了
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Spanish Clinical Research Network - SCReN積極的、募集していない
-
Inmunova S.A.Hospital Italiano de Buenos Aires; Laboratorio Elea Phoenix S.A.; Hospital de Campaña Escuela... と他の協力者完了
-
Manchester University NHS Foundation TrustUniversity of Manchester完了
-
Rush University Medical CenterHospital Civil de Guadalajara完了
-
Sinovac Research and Development Co., Ltd.完了
-
Mabwell (Shanghai) Bioscience Co., Ltd.Shanghai Public Health Clinical Center完了
Sm-EMAの臨床試験
-
Northeastern UniversityNational Center for Advancing Translational Sciences (NCATS)完了
-
Massachusetts General HospitalBoston University募集
-
University Hospital, MontpellierCentre Hospitalier Universitaire de Nīmes; Instituto de Investigación Sanitaria de la Fundación... と他の協力者募集
-
University Hospital Inselspital, BerneImaCor, Inc.完了
-
G&E Herbal Biotechnology Co., LTD完了
-
Palmer College of ChiropracticUniversity of Iowa; National Center for Complementary and Integrative Health (NCCIH)完了